RxDoctor Payments Data

Mitchell Boxer, MD

Allergy · Great Neck, NYNPI 1669472676

Payments from drug & device makers

$332in general payments, 2019–2025

Across 16 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$67
  • Genentech USA, Inc.$57
  • Sanofi-aventis U.S. LLC$55
  • Shire North American Group Inc$52
  • Takeda Pharmaceuticals U.S.A., Inc.$37
  • Sanofi$18
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$27783%
  • Education$5517%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$332 in reported general payments places this provider in the 30th percentile of 92 allergy providers in New York.

See all allergy providers in New York

Medicare billing

Part B allowed, 2024
$835,696
Medicare patients
368
Services billed
25,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5057$257,756
Dupixent PenDupilumab54$254,056
NucalaMepolizumab21$166,285
Dupixent SyringeDupilumab26$98,288
HizentraImmun Glob G(Igg)/Pro/Iga 0-5012$95,095
XolairOmalizumab30$85,794
Fasenra PenBenralizumab15$83,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$44,821
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$44,305
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$36,156
Breo ElliptaFluticasone/Vilanterol65$32,093
Arnuity ElliptaFluticasone Furoate63$25,719
Spiriva RespimatTiotropium Bromide25$12,914
SymbicortBudesonide/Formoterol Fumarate34$8,373
Epinephrine35$6,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid$37$293,91275 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$67$268,918205 claims
CSL BehringHizentra$17$95,09512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 92 allergy providers in New York.

Other allergy in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →